Bank Of Nova Scotia Mirati Therapeutics, Inc. Transaction History

Bank Of Nova Scotia

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	BUY	$41.99 - $62.38 $3.02 Million - $4.49 Million	72,000 New	72,000 $4.23 Million
Q1 2023 May 11, 2023	SELL	$36.54 - $54.26 $11.5 Million - $17 Million	-313,628 Reduced 75.88%	99,705 $3.71 Million
Q4 2022 Feb 09, 2023	BUY	$41.27 - $98.62 $3.82 Million - $9.13 Million	92,569 Added 28.86%	413,333 $18.7 Million
Q3 2022 Nov 10, 2022	SELL	$59.5 - $86.7 $31 Million - $45.1 Million	-520,236 Reduced 61.86%	320,764 $22.4 Million
Q2 2022 Aug 08, 2022	BUY	$39.16 - $88.71 $32.9 Million - $74.6 Million	841,000 New	841,000 $56.5 Million
Q2 2022 Aug 05, 2022	SELL	$39.16 - $88.71 $4.31 Million - $9.76 Million	-110,000 Closed	0 $0
Q1 2022 May 09, 2022	BUY	$75.82 - $150.97 $3.95 Million - $7.87 Million	52,117 Added 90.04%	110,000 $9.04 Million
Q4 2021 Feb 11, 2022	BUY	$132.01 - $190.29 $7.64 Million - $11 Million	57,883 New	57,883 $8.49 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Bank Of Nova Scotia, based on Form 13F filings with the SEC.

Stay updated on Bank Of Nova Scotia with notifications on news.